NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ESLA

Estrella Immunopharma Inc

May 08 • 04:00PM ET

1.16

Dollar change +0.04
Percentage change 3.57	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA NVAX BNTX PFE JNJ REGN GILD VRTX AZN LLY

| Held by: VTI IWC VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.24	Insider Own	72.09%	Shs Outstand	36.68M	Perf Week	1.75%
Market Cap	41.95M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.10M	Perf Month	32.57%
Income	-8.85M	PEG	-	EPS next Q	-0.11	Inst Own	0.81%	Short Float	0.02%	Perf Quarter	0.87%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	47.34%	Short Ratio	0.02	Perf Half Y	48.24%
Book/sh	0.00	P/B	295.92	EPS next Y	-	ROA	-140.57%	Short Interest	0.00M	Perf Year	16.00%
Cash/sh	0.03	P/C	45.60	EPS next 5Y	-	ROE	-192.50%	52W Range	0.63 - 3.23	Perf YTD	-3.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-6155.69%	52W High	-64.09%	Beta	0.41
Dividend TTM	-	Quick Ratio	0.55	Sales past 5Y	-	Gross Margin	-	52W Low	84.13%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	0.55	EPS Y/Y TTM	-32.57%	Oper. Margin	-	RSI (14)	63.30	Volatility	12.31% 11.18%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	16.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	1.38%	Payout	-	Rel Volume	0.04	Prev Close	1.12
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	89.83K	Price	1.16
SMA20	16.82%	SMA50	20.21%	SMA200	5.82%	Trades		Volume	3,635	Change	3.57%

Mar-05-25 08:00AM	Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners (Business Wire)
Feb-22-25 08:55AM	Estrella Immunopharma completes first dose cohort in STARLIGHT trial (TipRanks)
Feb-21-25 08:30AM	Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort (Business Wire)
Feb-19-25 04:46PM	Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital (Business Wire) +8.76%
Sep-27-24 12:00PM	Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS T-cells (Business Wire) +22.69%
12:00PM	Loading…
Aug-14-24 12:00PM	Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member (Business Wire)
Aug-02-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -18.08%
May-20-24 10:52AM	ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024 (InvestorPlace)
Sep-29-23 10:34AM	TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination (PR Newswire) -6.22%
Sep-18-23 05:00PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire) +34.29% -17.25%
Aug-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-12-23 07:00AM	TradeUP Acquisition Corp. Announces Meeting Date for Stockholders to Approve the Business Combination with Estrella Biopharma, Inc. and Liquidation of Investments Held in the Trust Account into Cash (PR Newswire)

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ESLA

Estrella Immunopharma Inc

Upgrade your FINVIZ experience